Simplifying Adeno-Associated Virus Vector Production
Recombinant Adeno-associated virus (rAAV) is the viral vector of choice for many ground-breaking research and clinical applications. The vector is being utilized in gene therapy to treat rare genetic diseases, as well as clinical studies for treating a range of diseases with broader indications. This means global demand for high quality rAAV manufacturing is escalating. Here, we explore various aspects of upstream rAAV production. We discuss the challenges that rAAV experts face and the best practice solutions they have employed to overcome them. Learn how combining new technology such as high throughput mini bioreactors and Design of Experiments (DOE) software can help rapidly optimize rAAV production.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.